Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Xenon Pharmaceuticals (XENE) PT Raised to $8 at Jefferies Following New Epilepsy Asset
May 10, 2017 10:35 AM EDTJefferies raised its price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $8.00 (from $7.00) while maintaining a Buy rating. The company added a new epilepsy asset, XEN1101, to their portfolio.
TV-45070 topline results are expected mid-2017. An IND for '901 is planned for 4Q17, and... More



